Mylan seeks approval for generic migraine drug
PITTSBURGH — Mylan announced Wednesday that it filed with the Food and Drug Administration for approval of a generic version of a drug for migraine headaches made by Endo Pharmaceuticals.
Mylan said it was the first to file for approval of a generic version of Frova (frovatriptan succinate EQ) tablets in the 2.5-mg strength. In response, Endo has filed a patent infringement lawsuit against Mylan in response to the filing.
Frova had sales of $68.2 million during the 12-month period ended in June, according to IMS Health.
Accelerating comps drive Target performance
MINNEAPOLIS — Target reported second-quarter earnings per share of $1.03 that beat analysts’ estimates by a nickel, and the company elevated its full-year profit forecast amid ongoing success of key initiatives.
Retail sales increased 5.1% to $15.9 billion from $15.1 billion, thanks to a 3.9% same-store sales increase and the addition of several new stores. Operating profit for the retail business increased at a slower rate, rising 4.6% to about $1.15 billion from nearly $1.1 billion.
Operating profits in the company’s credit card segment grew nearly 15% to $171 million from $149 million in the prior year, despite revenues that declined to $345 million from $406 million, as Target incurred just $15 million in bad debt expense, compared with $138 million the prior year.
“We’re very pleased with our second-quarter financial results, which benefited from acceleration in the pace of our comparable-store sales growth,” Target chairman, president and CEO Gregg Steinhafel said. “We continue to focus on strong execution of our strategy, preparing Target to perform well in a variety of economic environments.”
Second-quarter EPS of $1.03 were nearly 12% higher than the prior year’s 92 cents per share, while net income grew 3.7% to $704 million. Earnings per share grew at a faster rate due to an aggressive share repurchase program, which reduced the number of outstanding shares. The company said it spent $688 million during the second quarter to buy back 14.3 million shares at an average price of $48.11. At the midpoint of the year, the company has spent roughly $1.5 billion to buyback 29.7 million shares.
A third-quarter profit forecast of 70 cents to 75 cents encompassed analysts’ consensus estimate of 71 cents, however, the full-year outlook the company provided of $4.15 to $4.30 was higher that the $4.12 analysts envisioned.
One negative data point in the second-quarter results was the gross margin impact of some of the company’s key initiatives. The ongoing rollout of the PFresh format, with its expanded assortment of food and consumables, has a higher percentage of Target’s sales coming from lower margin goods. In addition, Target’s product assortment in these categories is competitively priced with Walmart. What’s more, gross margin pressure is compounded by the increased penetration rate of shoppers participating in the REDcard Rewards loyalty program, which deducts 5% from the purchase price at checkout. As a result, the gross margin rate declined to 31.6% in the second quarter from 32% the prior year and further declines are expected as the PFresh rollout continues and more customers participate in the 5% discount program.
Offsetting the lower margins, the company improved its expense control with selling, general and administrative expenses declining to 21.3% of sales, compared with 21.5% of sales.
Albertsons LLC names VP pharmacy operations
BOISE — Privately owned Albertsons LLC, which operates more than 200 pharmacies across six states, has named Stewart Edington VP pharmacy operations.
Edington has been with Albertsons stores since 2003, when he was hired as a pharmacy manager and worked in the company’s Phoenix stores. In 2006, Edington joined Albertsons LLC as the division pharmacy manager for the company’s Florida stores, a position he has held for the last five years.
Prior to working for Albertsons, Edington gained substantial pharmacy operations experience in his native South Africa in establishing and running four independent pharmacies over a seven-year period, and also was a health clinic manager for two years at a rural clinic.